Mesothelioma Ongoing Clinical Trials - Phase II

New York, New York: Memorial Sloan-Kettering Cancer Center

The purpose of this study is to use cone-beam CT scans to more accurately position the tumor during radiation and to see whether this method is more effective than the standard method of using 2D images (portal images), which is a type of X-ray. Cone-beam CT is a type of CT scanner attached to the treatment accelerator that produces 3D images of the patient.

Multiple Locations

The purpose of this study is to assess the efficacy of sunitinib malate, in terms of response rate (complete and partial), in patients with malignant pleural mesothelioma. To assess the toxicity, safety, and tolerability of this drug in these patients. To assess the duration of response or stable disease, stable disease rate, progression-free survival, and median and overall survival rates.

Houston, TX: Burzynski Clinic

Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. This phase II trial is studying how well antineoplaston therapy works in treating patients with advanced mesothelioma.

Edmonton, Alberta, Canada: Cross Cancer Institute at University of Alberta

Positron Emission Tomography (PET) is a specialized nuclear medicine procedure that uses positron emitting radio labeled tracer molecules to measure biological activity. This study will evaluate the effectiveness, value and safety of PET scanning in a number of uncommon cancers in the Canadian health care environment.

Multiple Locations

AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This Phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

Dallas, TX: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab.

Multiple Locations

Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma.

Edmonton, Alberta, Canada: Cross Cancer Institute at University of Alberta

This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy's ability to treat unusual shaped tumors, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness.

Multiple Locations

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.

Multiple Locations

The current study is designed to determine the response rate of oral Milataxel in patients with malignant mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

New York, NY: Memorial Sloan-Kettering Cancer Center

There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. The purpose of this study is to test the safety and toxicity of standard chemotherapy followed by IMRT.

Bethesda, MD: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

This Phase II trial is studying how well continuous hyperthermic peritoneal perfusion of cisplatin plus intraperitoneal infusions of paclitaxel and fluorouracil work in treating patients who have undergone surgery for peritoneal cancer.

Tampa, FL: H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

The purpose of this research study is to evaluate how effective the combination of Carboplatin, Bevacizumab (Avastin™) and, Pemetrexed (Alimta™) is in the treatment of patients with Malignant Pleural Mesothelioma (MPM). A combination of cisplatin and pemetrexed is considered standard for this disease and typically off protocol patients would receive cisplatin or carboplatin and pemetrexed as standard of care.

Los Angeles, CA: USC/Norris Comprehensive Cancer Center

This will be a single institution non-randomized phase I/II trial for patients with malignant mesothelioma stage II and above, who have not received prior chemotherapy for their disease. The purpose of this phase is to select a dose of VEGF-AS (antiangiogenesis drug) to be given with standard doses of pemetrexed followed by cisplatin on day 1 of a 21-day cycle.

Las Vegas, NV: Nevada Cancer Institute

The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at the MTD determined in the phase I part) in previously untreated, unresectable malignant pleural mesothelioma patients.